What is Curapel?
Curapel is a specialized biotechnology firm that emerged from the University of Manchester in 2014, focusing on the intersection of dermatological science and patient-centric care. The company distinguishes itself through the development of innovative, patent-protected products designed to mitigate the symptoms of chronic skin conditions. Its core portfolio includes Pellamex, a food supplement engineered to support skin barrier function, alongside topical solutions such as Pelladerm and Pellatone. By utilizing naturally occurring ingredients, Curapel addresses significant unmet clinical needs, positioning itself as a key player in the therapeutic dermatology sector. The company's market strategy revolves around providing safe, effective, and scientifically validated alternatives to traditional treatments, thereby improving the quality of life for individuals managing long-term skin inflammation and related disorders.
How much funding has Curapel raised?
Curapel has raised a total of $507K across 1 funding round:
Private Equity
$507K
Private Equity (2016): $507K with participation from Finance Wales and Lancaster Capital
Key Investors in Curapel
Finance Wales
The Development Bank of Wales provides sustainable and effective business finance solutions, including equity and loans, to support economic growth and technology ventures within the region.
Lancaster Capital
Lancaster Capital operates as a private fund and investment hub, connecting experienced business leaders to make strategic equity investments in high-potential ventures.
Undisclosed Investors
What's next for Curapel?
Looking ahead, the strategic deployment of the $507K will likely focus on scaling the commercialization of its existing product pipeline and advancing ongoing research initiatives. As Curapel transitions from its early-stage development phase into a more mature commercial entity, the focus will shift toward broader market penetration and potential clinical trials for new therapeutic candidates. The company's ability to maintain its intellectual property edge while navigating the regulatory complexities of the dermatological market will be critical. With the backing of institutional investors, Curapel is poised to refine its operational infrastructure, potentially exploring new distribution channels and partnerships that align with its long-term goal of becoming a leader in the global skin health market.
See full Curapel company page
